false 0001356090 0001356090 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 26, 2025

 

Precigen, Inc.

(Exact name of registrant as specified in its charter)

 

Virginia   001-36042   26-0084895

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

20374 Seneca Meadows Parkway, Germantown, Maryland 20876

(Address of principal executive offices) (Zip Code)

 

(301) 556-9900

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, No Par Value   PGEN   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 26, 2025 (the “2025 Annual Meeting”), the Company’s stockholders approved an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended (the “2023 Plan”), to increase the number of shares of common stock available for issuance thereunder by 11.5 million (the “2023 Plan Amendment No. 2”). The approval of the 2023 Plan Amendment No. 2 had been previously approved by the Company’s Board of Directors (the “Board”), subject to stockholder approval.

 

The 2023 Plan Amendment No. 2 amends the 2023 Plan, which was previously approved by the Company’s stockholders on June 8, 2023, and subsequently amended by the Company’s stockholders on July 5, 2024. The principal features of the 2023 Plan Amendment No. 2 are described in detail under “Proposal 6 - Approval of an Amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as Amended (the “2023 Plan”)” of the Company’s Definitive Proxy Statement on Schedule 14A for the 2025 Annual Meeting filed by the Company with the Securities and Exchange Commission on May 16, 2025 (the “Proxy Statement”). The full text of the 2023 Plan Amendment No. 2 is attached as Annex A to the Proxy Statement.

 

Item 5.07.Submission of Matters to a Vote of Security Holders.

 

At the 2025 Annual Meeting, the Company’s stockholders (i) elected each of the persons listed below as a director for a one-year term, (ii) approved an amendment to the Company’s Amended and Restated Articles of Incorporation to increase the Company’s authorized shares of common stock thereunder by 300 million, (iii) approved, in compliance with Nasdaq Listing Rule 5635(c), of the issuance of the Company’s shares of Series A Preferred Stock and Warrants to Randal J. Kirk as PIK dividends on the Series A Preferred Stock, in order for Mr. Kirk to receive PIK dividends on the Series A Preferred Stock on the same terms as the other investors, (iv) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, (v) approved a non-binding advisory resolution approving the compensation of the named executive officers, (vi) approved the 2023 Plan Amendment No. 2, and (vii) approved an amendment to the Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers to increase the number of shares of common stock which may be subject to awards thereunder by 1.1 million.

 

Proposal 1 - Election of directors.

 

  For   Against   Abstain   Broker Non-Votes
Randal Kirk 174,246,854   4,768,225   1,016,706   49,304,662
Nancy Howell Agee 173,396,985   5,390,070   1,244,730   49,304,662
Cesar Alvarez 160,583,877   19,128,648   319,260   49,304,662
Steven Frank 173,794,818   5,102,748   1,134,219   49,304,662
Vinita Gupta 174,703,376   4,982,011   346,398   49,304,662
Fred Hassan 174,576,158   5,131,655   323,972   49,304,662
Jeffrey Kindler 175,464,120   4,250,540   317,125   49,304,662
Helen Sabzevari 177,883,914   1,926,042   221,829   49,304,662
James Turley 174,538,663   5,171,322   321,800   49,304,662

 

Proposal 2 - Approval of an amendment to the Company’s Amended and Restated Articles of Incorporation to increase authorized shares of common stock thereunder by 300 million.

 

For Against Abstain
223,238,979 5,603,517 493,951

 

Proposal 3 - Approval, in compliance with Nasdaq Listing Rule 5625(c), of the issuance of the Company’s shares of Series A Preferred Stock and Warrants to Randal J. Kirk as PIK dividends on the Series A Preferred Stock, in order for Mr. Kirk to receive PIK dividends on the Series A Preferred Stock on the same terms as the other investors.

 

For Against Abstain Broker Non-Votes
167,387,561 11,685,114 959,110 49,304,662

 

 

 

Proposal 4 - Ratification of the Appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

 

For Against Abstain
228,912,465 373,134 50,848

 

Proposal 5 - Non-binding advisory resolution approving the compensation of the named executive officers.

 

For Against Abstain Broker Non-Votes
175,928,061 3,683,746 419,978 49,304,662

 

Proposal 6 - Approval of an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended, to increase the number of shares of common stock which may be subject to awards thereunder by 11.5 million.

 

For Against Abstain Broker Non-Votes
177,057,566 2,697,429 276,790 49,304,662

 

Proposal 7 - Approval of an amendment to the Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers, as amended, to increase the number of shares of common stock which may be subject to awards thereunder by 1.1 million.

 

For Against Abstain Broker Non-Votes
174,026,158 5,734,546 271,081 49,304,662

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

No.

  Description
     
104   Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Precigen, Inc.
   
     
  By:

/s/ Donald P. Lehr

    Donald P. Lehr
    Chief Legal Officer

 

Dated: June 30, 2025